Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

J Clin Oncol. 2015 Sep 20;33(27):3036-46. doi: 10.1200/JCO.2014.59.5256. Epub 2015 Aug 24.

Abstract

Ewing sarcoma (ES) is an aggressive sarcoma of bone and soft tissue occurring at any age with a peak incidence in adolescents and young adults. The treatment of ES relies on a multidisciplinary approach, coupling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy for control of the primary site and possible metastatic disease. The optimization of ES multimodality therapeutic strategies has resulted from the efforts of several national and international groups in Europe and North America and from cooperation between pediatric and medical oncologists. Successive first-line trials addressed the efficacy of various cyclic combinations of drugs incorporating doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide, and dactinomycin and identified prognostic factors now used to tailor therapies. The role of high-dose chemotherapy is still debated. Current 5-year overall survival for patients with localized disease is 65% to 75%. Patients with metastases have a 5-year overall survival < 30%, except for those with isolated pulmonary metastasis (approximately 50%). Patients with recurrence have a dismal prognosis. The many insights into the biology of the EWS-FLI1 protein in the initiation and progression of ES remain to be translated into novel therapeutic strategies. Current options and future approaches will be discussed.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Age of Onset
  • Bone Neoplasms / diagnosis
  • Bone Neoplasms / mortality
  • Bone Neoplasms / therapy*
  • Child
  • Cooperative Behavior
  • Diffusion of Innovation
  • Forecasting
  • Humans
  • Interdisciplinary Communication*
  • International Cooperation*
  • Medical Oncology / trends*
  • Pediatrics / trends*
  • Sarcoma, Ewing / diagnosis
  • Sarcoma, Ewing / mortality
  • Sarcoma, Ewing / therapy*
  • Survivors
  • Time Factors
  • Treatment Outcome
  • Young Adult